PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C12N 15/12, 15/11, C07K 14/47, C12Q 1/68, G01N 33/53, A61K 39/395, 31/70
A1

(11) International Publication Number: WO 00/56886

(43) International Publication Date: 28 September 2000 (28.09.00)

(21) International Application Number: PCT/GB00/01079

(22) International Filing Date: 22 March 2000 (22.03.00)

(30) Priority Data:
9906515.3 22 March 1999 (22.03.99) GB

(71) Applicant *(for all designated States except US)*: CANCER RESEARCH VENTURES LIMITED [GB/GB]; Cambridge House, 6–10 Cambridge Terrace, Regent's Park, London NW1 4JL (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: PELICCI, Pier, Giuseppe [IT/IT]; Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale, Via Ripamonti, 435, I–20141 Milan (IT). GIORGIO, Marco [IT/IT]; Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale, Via Ripamonti, 435, I–20141 Milan (IT). MIGLIACCIO, Enrica [IT/IT]; Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale, Via Ripamonti, 435, I–20141 Milan (IT). LANFRANCONE, Luisa [IT/IT]; Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale, Via Ripamonti, 435, I–20141 Milan (IT).

(74) Agents: CRIPPS, Joanna, E. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION



(57) Abstract

It has been determined that i) $p66^{shc}$ is serine phosphorylated upon UV treatment or oxidative damage; ii) the serine–phosphorylation of p66 by oxidative signals is mediated by Erk1 and p38, as shown both in vivo and in vitro; iii) ablation of $p66^{shc}$ expression by homologous recombination enhances resistance to oxidative damage both *in vitro* and *in vivo*; iv) a serine–phosphorylation defective mutant of $p66^{shc}$ is unable to restore a normal stress response in $p66^{shc}$ targeted cells; v) mice carrying the $p66^{shc}$ targeted mutation have prolonged lifespan.